Akorn Receives Product Approval
10 Oktober 2018 - 1:05PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that it has received a new
Abbreviated New Drug Application (ANDA) approval from the U.S. Food
and Drug Administration (FDA) for Bimatoprost Ophthalmic Solution,
0.03%. The product is manufactured at Akorn’s Amityville, New
York manufacturing facility.
According to IQVIA, sales of bimatoprost ophthalmic solution,
0.03% were approximately $63.5 million for the twelve months ended
August 2018.
Bimatoprost ophthalmic solution, 0.03% is indicated to treat
hypotrichosis of the eyelashes by increasing their growth including
length, thickness and darkness.
About AkornAkorn, Inc. is a specialty generic
pharmaceutical company engaged in the development, manufacture and
marketing of multisource and branded pharmaceuticals. Akorn has
manufacturing facilities located in Decatur, Illinois; Somerset,
New Jersey; Amityville, New York; Hettlingen, Switzerland and
Paonta Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
Echtzeit-Nachrichten über Akorn Inc (NASDAQ): 0 Nachrichtenartikel
Weitere News-Artikel